Core Viewpoint - The company reported a significant increase in revenue and gross profit for the fiscal year ending December 31, 2024, primarily driven by the sales of its core product, Huatangning, which has been included in the national medical insurance drug list in China, indicating strong future sales potential [1][2] Financial Performance - Revenue for the fiscal year reached 256 million RMB, a year-on-year increase of 234.02% [1] - Gross profit amounted to 125 million RMB, reflecting a year-on-year increase of 233.72% [1] - Research and development expenses were 215 million RMB, up 25.39% year-on-year [1] Product Sales and Market Expansion - Approximately 2.105 million boxes of Huatangning were sold, generating sales of about 256 million RMB, compared to 251,000 boxes and 76.6 million RMB in the previous year [1] - Huatangning is now available in around 2,700 hospitals across mainland China [2] - The company has taken over the commercialization of Huatangning from Bayer Pharmaceuticals, with a new sales leader appointed to drive market efforts [2] Future Outlook - The inclusion of Huatangning in the national medical insurance list is expected to significantly boost sales in the coming years [1] - In the first two months of 2025, approximately 592,000 boxes of Huatangning were sold, generating net sales of about 73.2 million RMB, compared to 202,000 boxes and 24.5 million RMB in the same period of 2024, indicating a 199% increase in sales despite stable pricing [2]
华领医药-B发布年度业绩 毛利1.25亿元 同比增加233.72%